Vitamin D Receptor (VDR) Gene Polymorphisms and High-Turnover Renal Osteodystrophy or Secondary Hyperparathyroidism in End-Stage Renal Disease: A Systematic Review

• Published in: Curēus (Palo Alto, CA) CA), 2024-07, Vol.16 (7), p.e64925
• Main Authors: Sinha, Tanya, Mushtaq, Muhammad Muaz, Ali, Husnain, Liaqat, Maryyam, Mushtaq, Maham, Sarwar, Muhammad Ahmad, Sarwer, Muhammad Asad, Bakht, Danyal, Fatima, Rida, Bokhari, Syed Faqeer Hussain
• Format: Article
• Language: English
• Subjects: Bone density; Clinical outcomes; Disease prevention; Endocrinology/Diabetes/Metabolism; Genotype & phenotype; Hemodialysis; Internal Medicine; Kidney diseases; Metabolism; Mortality; Nephrology; Patients; Systematic review; Transplants & implants; Vitamin D
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.64925

Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are often complicated by high-turnover renal osteodystrophy (HTRO) and secondary hyperparathyroidism (SHPT), characterized by disturbances in mineral metabolism and skeletal abnormalities. Genetic variations within the vitamin D receptor (VDR) gene, known as VDR gene polymorphisms, have been implicated in modulating the susceptibility to HTRO and SHPT. This systematic review aims to evaluate the existing literature on the association between VDR gene polymorphisms and the development of these complications in ESRD and hemodialysis patients. A comprehensive literature search across multiple databases was conducted, and studies investigating VDR gene polymorphisms and HTRO or SHPT in ESRD or hemodialysis patients were included. The included studies examined various VDR gene polymorphisms, such as BsmI, ApaI, TaqI, and FokI, and their associations with clinical outcomes like parathyroid hormone (PTH) levels, bone mineral density, and the development of SHPT or HTRO. The findings suggest that certain VDR gene polymorphisms, notably the ApaI "aa" genotype, BsmI "bb" genotype, TaqI "tt" genotype, and FokI variant, may contribute to the pathogenesis of SHPT and HTRO by affecting PTH levels, bone turnover markers, and vitamin D sensitivity. However, the studies had relatively small sample sizes and were conducted in different populations, limiting generalizability. Further larger-scale studies, functional investigations, and exploration of gene-environment interactions are warranted to elucidate the underlying mechanisms and facilitate personalized treatment approaches for CKD and ESRD patients with mineral and bone disorders.